A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection
Frontiers in Cellular and Infection Microbiology · 2024
DOI: 10.3389/fcimb.2024.1381877 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Qianyun Liu und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology, Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Most of vaccinees and COVID-19 convalescents can build effective anti-SARS-CoV-2 humoral immunity, which helps preventing infection and alleviating symptoms. However, breakthrough viral infections caused by emerging SARS-CoV-2 variants, especially Omicron subvariants, still pose a serious threat to global health. By monitoring the viral infections and the sera neutralization ability of a long-tracked cohort, we found out that the immune evasion of emerging Omicron subvariants and the decreasing neutralization led to the mini-wave of SARS-CoV-2 breakthrough infections. Meanwhile, no significant difference had been found in the infectivity of tested SARS-CoV-2 variants, even though the affinity between human angiotensin-converting enzyme 2 (hACE2) and receptor-binding domain (RBDs) of tested variants showed an increasing trend. Notably, the immune imprinting of inactivated COVID-19 vaccine can be relieved by infections of BA.5.2 and XBB.1.5 variants sequentially. Our data reveal the rising reinfection risk of immune evasion variants like Omicron JN.1 in China, suggesting the importance of booster with updated vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Virology, Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
- State Key Laboratory of Virology, College of Life Sciences, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China.
- State Key Laboratory of Virology, Modern Virology Research Center and RNA Institute, College of Life Sciences and Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan, China.
- Huzhou Center for Disease Control and Prevention, Huzhou, China.
- Hubei Center for Disease Control and Prevention, Wuhan, China.
- Department of Respiratory and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan, China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Liu, Q., Jin, M., Mei, F., Fan, H., Gu, M., Zhang, Y., Qian, S., Tan, X., Ji, L., Zhang, Z., Chen, G., Yan, H., Chen, Y., Lan, K., Geng, Q., Cai, K., & Zhou, L. (2024). A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1381877
Vancouver
Liu Q, Jin M, Mei F, Fan H, Gu M, Zhang Y, et al. A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1381877
BibTeX
@article{Liu2024,
author = {Liu, Qianyun and Jin, Meihua and Mei, Fanghua and Fan, Hui and Gu, Mengxue and Zhang, Yuzhen and Qian, Shengnan and Tan, Xue and Ji, Lei and Zhang, Zhen and Chen, Guozhong and Yan, Huan and Chen, Yu and Lan, Ke and Geng, Qing and Cai, Kun and Zhou, Li},
title = {A long-term cohort study: the immune evasion and decreasing neutralization dominated the SARS-CoV-2 breakthrough infection},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2024},
doi = {10.3389/fcimb.2024.1381877}
}
EUVIMED